X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.fiercepharma.com/marketing/lillys-jaypirca-tipped-capture-60-btk-leukemia-market-leaving-astrazeneca-beigene-dust
https://www.prnewswire.com/news-releases/updated-data-from-the-bruin-phase-12-study-of-pirtobrutinib-in-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-presented-at-the-2023-ash-annual-meeting-302011905.html
https://www.fiercepharma.com/pharma/lillys-jaypirca-blazes-leukemia-trail-fda-nod-fast-confirmatory-trial-filing
https://www.prnewswire.com/news-releases/jaypirca-pirtobrutinib-now-approved-by-us-fda-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-who-have-received-at-least-two-lines-of-therapy-including-a-btk-inhibitor-and--302003695.html
https://www.ema.europa.eu/en/documents/overview/jaypirca-epar-medicine-overview_en.pdf
https://www.prnewswire.com/news-releases/lilly-announces-details-of-pirtobrutinib-presentations-in-b-cell-malignancies-at-2023-ash-annual-meeting-301974498.html
https://www.prnewswire.com/news-releases/lilly-highlights-verzenio-abemaciclib-and-jaypirca-pirtobrutinib-data-at-2023-asco-annual-meeting-301840771.html
https://www.prnewswire.com/news-releases/lunsumio-jaypirca-available-at-alliancerx-walgreens-pharmacy-for-treatment-of-two-forms-of-non-hodgkin-lymphoma-301826773.html
https://endpts.com/lilly-enters-ripe-btk-field-with-quick-fda-nod-in-mantle-cell-lymphoma/
https://www.fiercepharma.com/pharma/eli-lilly-committed-gip-class-expects-over-30-billion-2023-revenues-4-new-product-launches
https://www.fiercebiotech.com/biotech/eli-lilly-pads-novel-btks-case-amid-fda-review-need-not-worry
https://endpts.com/ash22-lillys-loxo-rounds-out-the-phi-ii-data-for-lymphoma-drug-under-fda-review/
Market Place
Share 
